Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10109563 | 1.00 | ESR1 (0.41) | ESR1ESR2SHBGHSP90AA1HSP90AB1 | |
| SCHEMBL10109552 | 0.92 | ESR1 (0.40) | ESR1ESR2SHBGDRD2DRD1 | |
| SCHEMBL317980 | 0.92 | ESR1 (0.40) | ESR1ESR2SHBGDRD2DRD1 | |
| SCHEMBL10109554 | 0.86 | ESR1 (0.47) | ESR1ESR2SHBGDRD2DRD1 | |
| SCHEMBL318429 | 0.86 | ESR1 (0.47) | ESR1ESR2SHBGDRD2DRD1 | |
| SCHEMBL317766 | 0.84 | ESR1 (0.45) | ESR1ESR2SHBGDRD2DRD1 | |
| SCHEMBL10109560 | 0.84 | ESR1 (0.45) | ESR1ESR2SHBGDRD2DRD1 | |
| SCHEMBL318777 | 0.81 | ESR1 (0.43) | ESR1ESR2SHBGDRD2DRD1 | |
| SCHEMBL10109546 | 0.81 | ESR1 (0.43) | ESR1ESR2SHBGDRD2DRD1 | |
| SCHEMBL318350 | 0.81 | CYP3A4 (0.47) | ESR1ESR2SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1853578-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006088716-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ESR2, ERLIN1, ESRRG | ESR1 6/4885ESR2 1/4885SHBG 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.